Compare XZO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XZO | SLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 2007 |
| Metric | XZO | SLS |
|---|---|---|
| Price | $15.27 | $13.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $25.25 | ★ $37.50 |
| AVG Volume (30 Days) | 236.1K | ★ 12.9M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 50.00 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $216,980,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.64 | N/A |
| P/E Ratio | $20.85 | ★ N/A |
| Revenue Growth | ★ 61.99 | N/A |
| 52 Week Low | $12.36 | $1.39 |
| 52 Week High | $24.60 | $24.89 |
| Indicator | XZO | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 60.23 |
| Support Level | $15.03 | $9.36 |
| Resistance Level | $17.25 | $15.77 |
| Average True Range (ATR) | 0.83 | 1.77 |
| MACD | -0.24 | 0.98 |
| Stochastic Oscillator | 3.11 | 43.49 |
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.